CRISPR Therapeutics AG (CRSP)

Over the past six months, CRISPR Therapeutics' stock price has been impacted by several events. A convertible senior notes offering in March 2026 provided capital but potentially diluted shares. Business updates and financial results in February 2026 influenced investor sentiment. Positive Phase 1 clinical data for CTX310 was announced in November 2025, and analyst ratings were adjusted. The commercialization of CASGEVY, led by Vertex Pharmaceuticals, showed increasing patient initiations and revenue growth. The stock price increased by 50.96% over the past year, with a 52-week range between $33.03 and $78.48, and a share price of $51.72 as of April 9, 2026.

The demand for CRISPR Therapeutics AG's products is not typically subject to traditional consumer demand seasonality. Instead, demand is driven by factors such as disease prevalence, clinical trial progress and regulatory approvals, patient initiations and commercialization ramp-up, and healthcare system adoption and reimbursement. The increasing patient initiations for CASGEVY indicate a growing demand for this therapy. Demand is more likely to be influenced by medical need, clinical success, and market access rather than cyclical consumer patterns.

CRISPR Therapeutics AG is a Swiss-American biotechnology company focused on developing gene-based medicines for serious human diseases, operating within the Healthcare sector and Biotechnology industry. Their core technology is the CRISPR/Cas9 platform, enabling precise alterations of genomic DNA. Their major product is CASGEVY (exagamglogene autotemcel [exa-cel]), a gene-edited cell therapy developed with Vertex Pharmaceuticals, which received regulatory approval in the United States, Great Britain, and Bahrain in late 2023 for eligible patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT). The company has a diverse pipeline of therapeutic programs across various disease areas, including Hemoglobinopathies, Immuno-Oncology, Regenerative Medicine, Cardiovascular and Autoimmune Conditions, Rare Diseases, Type 1 Diabetes, and other partnered programs.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its U.S. subsidiary, CRISPR Therapeutics, Inc., operating R&D facilities in Boston, Massachusetts, and San Francisco, California. It also has a manufacturing facility in Framingham, Massachusetts, and offices in London, United Kingdom. Its global footprint supports clinical trials across North America and Europe.

CRISPR Therapeutics has maintained a strong brand reputation over the past year. The company was named to TIME's Most Influential Companies list in June 2025 and received historic regulatory approvals for CASGEVY. It has also received accolades such as the NEVY Award in Patient Impact 2024, SCRIP Award 2024, and recognition on TIME Best Inventions 2024 and Fierce50 Honoree in Innovation 2024. The company continues to be recognized for its scientific innovation, with ongoing clinical trials and preclinical data presentations. No significant negative events impacting CRISPR Therapeutics AG's reputation in the past year were found.

CRISPR Therapeutics AG is primarily owned by institutional shareholders, with 498 institutional owners holding 76,371,827 shares as of April 9, 2026. Major institutional owners include ARK Investment Management LLC, BlackRock, Inc., Orbis Allan Gray Ltd, Capital International Investors, State Street Corp, T. Rowe Price Investment Management, Inc., Glaxosmithkline Plc, UBS Group AG, Vanguard Group Inc, and Geode Capital Management, Llc. Celgene Corp is the largest individual shareholder, owning 8.56 million shares, representing 8.92% of the company. Institutional shareholders hold 79.69% of the stock, while insiders hold 35.88%.